Literature DB >> 16939521

Recurrent glomerulonephritis after kidney transplantation.

B Y Choy1, T M Chan, K N Lai.   

Abstract

Thirty to fifty percent of kidney transplant recipients have glomerular diseases as the underlying causes of end-stage renal failure. While recurrence of glomerulonephritis is an important cause of late renal allograft failure, the risk factors for recurrence are largely unknown or imprecise and prediction remains difficult. Recurrent disease usually presents with similar manifestations as the native disease. With regard to treatment of recurrent glomerular disease in the renal allograft, plasma exchange may be effective in reducing proteinuria in patients with early recurrence of focal and segmental glomerulosclerosis, but immunosuppressive therapy is generally ineffective in the prevention or treatment of recurrent disease. General supportive measures including strict blood pressure control and inhibition or blockade of the rennin-angiotensin pathway are helpful in retarding the rate of deterioration in renal allograft function. Despite the risk of recurrence, kidney transplantation following primary glomerulonephritides enjoys graft and patient survival rates comparable to other causes of end-stage renal failure. With a few exceptions, living related renal transplantation is not contraindicated in view of the favorable outcome and the donor shortage. This review discusses commonly encountered recurrent glomerulonephritides, with special emphasis on the influence of post-transplant prophylactic immunosuppression and emerging treatments.

Entities:  

Mesh:

Year:  2006        PMID: 16939521     DOI: 10.1111/j.1600-6143.2006.01502.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  41 in total

1.  Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.

Authors:  Sami Alasfar; Dany Matar; Robert A Montgomery; Niraj Desai; Bonnie Lonze; Vikas Vujjini; Michelle M Estrella; John Manllo Dieck; Gebran Khneizer; Sanja Sever; Jochen Reiser; Nada Alachkar
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

2.  Monozygotic transplantation: concerns and opportunities.

Authors:  N Krishnan; P M Buchanan; N Dzebisashvili; H Xiao; M A Schnitzler; D C Brennan
Journal:  Am J Transplant       Date:  2008-09-19       Impact factor: 8.086

3.  Recurrent FSGS Postkidney Transplant: Moving the Needle Forward.

Authors:  Sandra Amaral; Alicia Neu
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-20       Impact factor: 8.237

4.  Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States.

Authors:  Pavani Naini Reddy; Marcelo Santos Sampaio; Hung-Tien Kuo; Paul Martin; Suphamai Bunnapradist
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

Review 5.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 7.  Kidney transplantation in patients with systemic lupus erythematosus.

Authors:  Sophia Lionaki; Chrysanthi Skalioti; John N Boletis
Journal:  World J Transplant       Date:  2014-09-24

Review 8.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

Review 9.  Recurrent glomerulonephritis after renal transplantation: an unsolved problem.

Authors:  William A Golgert; Gerald B Appel; Sundaram Hariharan
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 8.237

Review 10.  Membranous nephropathy in children: clinical presentation and therapeutic approach.

Authors:  Shina Menon; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.